241 related articles for article (PubMed ID: 27742785)
1. Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters.
Payabyab EC; Balasubramaniam S; Edgerly M; Velarde M; Merino MJ; Venkatesan AM; Leuva H; Litman T; Bates SE; Fojo T
Clin Cancer Res; 2016 Oct; 22(20):4989-5000. PubMed ID: 27742785
[TBL] [Abstract][Full Text] [Related]
2. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
[TBL] [Abstract][Full Text] [Related]
3. Contemporary management of adrenocortical carcinoma.
Zini L; Porpiglia F; Fassnacht M
Eur Urol; 2011 Nov; 60(5):1055-65. PubMed ID: 21831516
[TBL] [Abstract][Full Text] [Related]
4. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis, treatment and outcome of adrenocortical cancer.
Mihai R
Br J Surg; 2015 Mar; 102(4):291-306. PubMed ID: 25689291
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival in recurrent adrenocortical cancer.
Shuayb M; Das A; Uddin MN
BMJ Support Palliat Care; 2019 Mar; 9(1):47-50. PubMed ID: 29903850
[TBL] [Abstract][Full Text] [Related]
7. Clinical presentation, treatment modalities and outcome in patients with adrenocortical carcinoma: A single center experience.
Bronswijk MJH; Laenen A; Bechter OE
Neoplasma; 2020 Jan; 67(1):209-213. PubMed ID: 31777255
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
9. Future directions in the diagnosis and medical treatment of adrenocortical carcinoma.
Creemers SG; Hofland LJ; Korpershoek E; Franssen GJ; van Kemenade FJ; de Herder WW; Feelders RA
Endocr Relat Cancer; 2016 Jan; 23(1):R43-69. PubMed ID: 26475053
[TBL] [Abstract][Full Text] [Related]
10. [Adrenocortical carcinoma and its treatment].
Tupikowski W; Bednarek-Tupikowska G; Florczak A
Postepy Hig Med Dosw (Online); 2004 Feb; 58():27-36. PubMed ID: 15069374
[TBL] [Abstract][Full Text] [Related]
11. Adrenocortical carcinoma.
Baudin E;
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):411-34. PubMed ID: 26038209
[TBL] [Abstract][Full Text] [Related]
12. Mitotane With or Without Cisplatin and Etoposide for Patients with a High Risk of Recurrence in Stages 1-3 Adrenocortical Cancer After Surgery.
Sarvestani AL; Gregory SN; Teke ME; Terzolo M; Berruti A; Hernandez JM; Habra MA
Ann Surg Oncol; 2023 Feb; 30(2):680-682. PubMed ID: 36305989
[No Abstract] [Full Text] [Related]
13. Long-Term Survival in a Patient With Metastatic DDR2-Positive Adrenal Cortical Carcinoma.
Taza F; Chovanec M; Hahn N; Albany C
Clin Genitourin Cancer; 2017 Oct; 15(5):e893-e895. PubMed ID: 28606737
[No Abstract] [Full Text] [Related]
14. [A Case Report of a Patient with Metastatic Adrenocortical Carcinoma who Received the Combination Etoposide, Doxorubicin, Cisplatin, and Mitotane Therapy and Achieved Remission].
Ueda S; Nakane K; Namiki S; Takeuchi Y; Kawase M; Takeuchi S; Kawase K; Nakai C; Kato D; Takai M; Iinuma K; Tsuchiya T; Miyazaki T; Koie T
Hinyokika Kiyo; 2022 May; 68(5):139-143. PubMed ID: 35748231
[TBL] [Abstract][Full Text] [Related]
15. Emerging drugs for adrenocortical carcinoma.
Berruti A; Ferrero A; Sperone P; Daffara F; Reimondo G; Papotti M; Dogliotti L; Angeli A; Terzolo M
Expert Opin Emerg Drugs; 2008 Sep; 13(3):497-509. PubMed ID: 18764725
[TBL] [Abstract][Full Text] [Related]
16. Update in adrenocortical carcinoma.
Fassnacht M; Kroiss M; Allolio B
J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734
[TBL] [Abstract][Full Text] [Related]
17. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.
Icard P; Goudet P; Charpenay C; Andreassian B; Carnaille B; Chapuis Y; Cougard P; Henry JF; Proye C
World J Surg; 2001 Jul; 25(7):891-7. PubMed ID: 11572030
[TBL] [Abstract][Full Text] [Related]
18. Advanced Adrenocortical Carcinoma - What to do when First-Line Therapy Fails?
Megerle F; Kroiss M; Hahner S; Fassnacht M
Exp Clin Endocrinol Diabetes; 2019 Feb; 127(2-03):109-116. PubMed ID: 30469158
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic treatment of adrenocortical carcinoma.
Ahlman H; Khorram-Manesh A; Jansson S; Wängberg B; Nilsson O; Jacobsson CE; Lindstedt S
World J Surg; 2001 Jul; 25(7):927-33. PubMed ID: 11572034
[TBL] [Abstract][Full Text] [Related]
20. Adrenocortical Carcinoma: Role of Adjuvant and Neoadjuvant Therapy.
Kenney L; Hughes M
Surg Oncol Clin N Am; 2023 Apr; 32(2):279-287. PubMed ID: 36925185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
